Skip to main content
American Journal of Respiratory and Critical Care Medicine logoLink to American Journal of Respiratory and Critical Care Medicine
letter
. 2022 Feb 23;205(9):1126–1127. doi: 10.1164/rccm.202112-2864LE

Reply to Bhatt and to Ramakrishnan et al.

Bartolome R Celli 1,*, Leonardo M Fabbri, on behalf of all the authors2
PMCID: PMC9851488  PMID: 35196478

From the Authors:

We appreciate the positive comments of Dr. Bhatt and Dr. Ramakrishnan and colleagues on the Rome proposal for an updated definition and severity classification of chronic obstructive pulmonary disease exacerbations (ECOPD) (1).

Dr. Bhatt expresses concerns that no minimum timing threshold was proposed for an ECOPD onset. About 50% of patients have a symptom worsening in the hours before ECOPD onset (2, 3), whereas the remaining 50% experience a prodrome of progressive increase of symptoms, including cough (2, 4). Importantly, not having an onset in the timing of ECOPD is supported by the fact that early intervention might impact favorably on outcomes of ECOPD (3, 4). A threshold in the change in the severity of individual or combined symptoms has been used to differentiate day-to-day symptom variation from the onset of an ECOPD (2); empirical research will validate the suggested threshold values that we have proposed (1).

The Rome proposal does not regard cough as a minor symptom. Indeed, Table 2 of the manuscript includes cough in the definition itself and the diagnostic approach to the patient. What was not done is to include cough as an objective measure of ECOPD severity, as we could not find any studies to support this. Further comments by Dr. Bhatt related to the difficulty in the use of the dyspnea visual analog scale are not well-founded since the visual analog scale has been used in several ECOPD studies and has been validated against respiratory loads in patients with COPD (5, 6). The same can be said for the use of respiratory rate, heart rate, and, most of all, oxygenation levels, now widely used in this time of the most severe ECOPDs experienced by some of our patients in their lifetime due to coronavirus disease (COVID-19) (7). Finally, Dr. Bhatt suggests that the criterion arterial oxygen saturation (SaO2) <92% may be problematic, particularly in patients treated with oxygen. However, SaO2 is just one of the five easy-to-evaluate parameters that we recommend to assess severity at the point of care (1).

Dr. Ramakrishnan and colleagues support the Rome proposal in adding objective markers of diagnosis and severity of ECOPD and the importance of comorbidities for ECOPD. However, they decry the specificity of the markers agreed on by the experts to include in the proposal. By including serum C-reactive protein, we decided to highlight the importance of inflammation in the assessment of ECOPD severity (1). We believe it is wise to learn from other fields, particularly the successful story of the diagnosis of myocardial injury, which started as a clinical syndrome of angina, to which was first added electrocardiogram changes, and subsequently the abnormal elevation of noncardiac-specific enzyme markers (creatine phosphokinase, serum glutamic oxalacetic transaminase, and lactate dehydrogenase). The specific troponin marker (8) has only been in use in the last three decades but resulted from a progressive evolution, narrowing the definition to a specific event defined as myocardial injury. Remaining anchored to a subjective definition that includes different episodes that may resemble an ECOPD, where the event ends up being only “a diagnosis of exclusion” will not facilitate novel approaches to better manage the episode. None of the major acute events such as acute respiratory distress syndrome, myocardial infarction, stroke, and sepsis, which cause as many deaths as ECOPD, are diagnosed by “exclusion.” Progress in their management has been driven by definitions based on subjective and objective markers that have evolved over time. Finally, the argument that, currently, many outpatients develop values that are above the thresholds suggested in the Rome proposal (and that many inpatients do not) is precisely the reason to grade severity based on objective parameters determined at the point of contact. Perhaps some of those patients were managed in the wrong setting.

Dr. Bhatt wisely states that “Rome was not built in one day.” We agree, as our work is a “proposal” that intends to improve on a definition that has not evolved, notably Laennec’s work in 1821 (9). Using another Italian saying, “perfection is the enemy of the good,” the Rome proposal may not be perfect, but through empirical research, it can serve as the foundation to move this field forward.

Footnotes

Originally Published in Press as DOI: 10.1164/rccm.202112-2864LE on February 23, 2022

Author disclosures are available with the text of this letter at www.atsjournals.org.

References

  • 1. Celli BR, Fabbri LM, Aaron SD, Agusti A, Brook R, Criner GJ, et al. An updated definition and severity classification of COPD exacerbations: The Rome proposal. Am J Respir Crit Care Med . 2021;204:1251–1258. doi: 10.1164/rccm.202108-1819PP. [DOI] [PubMed] [Google Scholar]
  • 2. Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax . 2012;67:238–243. doi: 10.1136/thoraxjnl-2011-200768. [DOI] [PubMed] [Google Scholar]
  • 3. Chandra D, Tsai CL, Camargo CA., Jr Acute exacerbations of COPD: delay in presentation and the risk of hospitalization. COPD . 2009;6:95–103. doi: 10.1080/15412550902751746. [DOI] [PubMed] [Google Scholar]
  • 4. Calverley P, Pauwels Dagger R, Löfdahl CG, Svensson K, Higenbottam T, Carlsson LG, et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J . 2005;26:406–413. doi: 10.1183/09031936.05.00143404. [DOI] [PubMed] [Google Scholar]
  • 5. Pinto-Plata VM, Livnat G, Girish M, Cabral H, Masdin P, Linacre P, et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest . 2007;131:37–43. doi: 10.1378/chest.06-0668. [DOI] [PubMed] [Google Scholar]
  • 6. Noell G, Cosío BG, Faner R, Monsó E, Peces-Barba G, de Diego A, et al. Multi-level differential network analysis of COPD exacerbations. Eur Respir J . 2017;50:1700075. doi: 10.1183/13993003.00075-2017. [DOI] [PubMed] [Google Scholar]
  • 7. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med . 2020;383:1757–1766. doi: 10.1056/NEJMcp2009249. [DOI] [PubMed] [Google Scholar]
  • 8. Hamm CW, Ravkilde J, Gerhardt W, Jørgensen P, Peheim E, Ljungdahl L, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med . 1992;327:146–150. doi: 10.1056/NEJM199207163270302. [DOI] [PubMed] [Google Scholar]
  • 9.Laennec R. In: A treatise on the diseases of the chest. Forbes J, editor. London: T and G Underwood; 1821. [Google Scholar]

Articles from American Journal of Respiratory and Critical Care Medicine are provided here courtesy of American Thoracic Society

RESOURCES